UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant |X|
Filed by a Party other than the Registrant |_|
Check the appropriate box:
|_| Preliminary Proxy Statement
|_| Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
|X| Definitive Proxy Statement
|_| Definitive Additional Materials
|_| Soliciting Material Under Rule 14a-12
SIGA TECHNOLOGIES, INC.
(Name of Registrant as Specified in Its Charter)
N/A
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|X| No fee required
|_| Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11
(1) Title of each class of securities to which transaction applies:
_______________________________________________________________
(2) Aggregate number of securities to which transaction applies:
_______________________________________________________________
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the
amount on which the filing fee is calculated and state how it
was determined):
_______________________________________________________________
(4) Proposed maximum aggregate value of transaction:
_______________________________________________________________
(5) Total fee paid:
_______________________________________________________________
|_| Fee paid previously with preliminary materials.
|_| Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
_______________________________________________________________
(2) Form, Schedule or Registration Statement No.:
_______________________________________________________________
(3) Filing Party:
_______________________________________________________________
(4) Date Filed:
_______________________________________________________________
SIGA Technologies, Inc.
420 Lexington Avenue, Suite 408
New York, New York 10170
(212) 672-9100
June 15, 2007
Dear Stockholder:
You are cordially invited to attend the Special Meeting of Stockholders of
SIGA Technologies, Inc. which will be held at the offices of Kramer Levin
Naftalis & Frankel LLP, 1177 Avenue of the Americas, 29th Floor, New York, New
York 10036 at 10:00 a.m. (local time) on July 26, 2007, and at any adjournment
or postponement thereof. On the following pages you will find the formal notice
of special meeting and proxy statement.
To assure that you are represented at the Special Meeting, whether or not
you plan to attend the meeting in person, please read carefully the accompanying
proxy statement, which describes the matters to be voted upon, and please
complete, date, sign and return the enclosed proxy card promptly.
I hope that you will attend the meeting and I look forward to seeing you
there.
Sincerely,
/s/ Eric A. Rose
-----------------
Eric A. Rose, M.D.
Chief Executive Officer
and Chairman of the Board
SIGA Technologies, Inc.
420 Lexington Avenue, Suite 408
New York, New York 10170
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON JULY 26, 2007
NOTICE IS HEREBY GIVEN that the Special Meeting of Stockholders (the
"Special Meeting") of SIGA Technologies, Inc., a Delaware corporation ("SIGA"),
will be held on Thursday, July 26, 2007, at 10:00 a.m. (local time), at the
offices of Kramer Levin Naftalis & Frankel LLP, 1177 Avenue of the Americas,
29th Floor, New York, New York 10036, and at any adjournment.
At the Special Meeting, SIGA's stockholders will be voting on a proposal
to do the following:
1. To amend the certificate of incorporation to increase authorized
common stock by 50,000,000 shares to 100,000,000 shares of common
stock.
Stockholders of record at the close of business on June 14, 2007 are
entitled to notice of, and to vote at, the Special Meeting or any adjournment or
postponement thereof. A list of such stockholders will be available at the
Special Meeting and for any purpose related to the Special Meeting, during the
ten days prior to the Special Meeting, at SIGA's office, during ordinary
business hours.
All stockholders are cordially invited to attend the Special Meeting. If
you do not expect to be present at the Special Meeting, you are requested to
fill in, date and sign the enclosed proxy and mail it promptly in the enclosed
envelope to make sure that your shares are represented at the Special Meeting.
In the event you decide to attend the Special Meeting in person, you may, if you
desire, revoke your proxy and vote your shares in person.
YOUR VOTE IS IMPORTANT
IF YOU ARE UNABLE TO BE PRESENT PERSONALLY, PLEASE MARK, SIGN AND DATE THE
ENCLOSED PROXY, WHICH IS BEING SOLICITED BY THE BOARD OF DIRECTORS, AND RETURN
IT PROMPTLY IN THE ENCLOSED ENVELOPE.
By Order of the Board of Directors,
/s/ Thomas N. Konatich
-----------------------
Thomas N. Konatich
Secretary
New York, New York
June 15, 2007
SIGA Technologies, Inc.
420 Lexington Avenue, Suite 408
New York, New York 10170
--------------
PROXY STATEMENT
SPECIAL MEETING OF STOCKHOLDERS
JULY 26, 2007
--------------
This proxy statement is furnished to stockholders of SIGA Technologies,
Inc. ("SIGA") in connection with the solicitation of proxies, in the
accompanying form, by the Board of Directors of SIGA (the "Board of Directors")
for use in voting at the Special Meeting of Stockholders (the "Special Meeting")
to be held at the offices of Kramer Levin Naftalis & Frankel LLP, 1177 Avenue of
the Americas, 29th Floor, New York, New York 10036, on Thursday, July 26, 2007,
at 10:00 a.m., and at any adjournment or postponement thereof.
This proxy statement, and the accompanying form of proxy, are first being
mailed to stockholders on or about June 20, 2007.
VOTING RIGHTS AND SOLICITATION OF PROXIES
Purpose of the Special Meeting
The specific proposal to be considered and acted upon at the Special
Meeting is summarized in the accompanying Notice of Special Meeting of
Stockholders. The proposal is described in more detail in this proxy statement.
Record Date and Outstanding Shares
The Board of Directors has fixed the close of business on June 14, 2007 as
the record date (the "Record Date") for the determination of stockholders
entitled to notice of, and to vote at, the Special Meeting. Only stockholders of
record at the close of business on the Record Date will be entitled to vote at
the Special Meeting or any and all adjournments or postponements thereof. As of
the Record Date, SIGA had issued and outstanding 33,491,478 shares of common
stock, par value $.0001 per share.
Voting at the Special Meeting
Each share of common stock outstanding on the Record Date will be entitled
to one vote on the matter submitted to a vote of the stockholders.
The presence, in person or by proxy, of the holders of a majority of the
votes entitled to be cast by the stockholders entitled to vote at the Special
Meeting is necessary to constitute a quorum. Abstentions and broker "non-votes"
are counted as present and entitled to vote for purposes of determining a
quorum. A broker "non-vote" occurs when a nominee holding shares for a
beneficial owner does not vote on a particular proposal because the nominee does
not have discretionary voting power for that particular item and has not
received instructions from the beneficial owner.
For the amendment of the certificate of incorporation to increase
authorized common stock by 50,000,000 shares to 100,000,000 shares of common
stock, the affirmative vote of a majority of the total votes entitled to be cast
by the stockholders on such proposal in person or by proxy at the Special
Meeting is required. Abstentions and broker "non-votes" for such proposal are
not considered to have been voted on the proposal.
1
Revocability and Voting of Proxies
Any person signing a proxy in the form accompanying this proxy statement
has the power to revoke it prior to the Special Meeting or at the Special
Meeting prior to the vote pursuant to the proxy. A proxy may be revoked by any
of the following methods:
o by writing a letter delivered to Thomas N. Konatich, Secretary of SIGA,
stating that the proxy is revoked;
o by submitting another proxy with a later date; or
o by attending the Special Meeting and voting in person.
Please note, however, that if a stockholder's shares are held of record by
a broker, bank or other nominee and that stockholder wishes to vote at the
Special Meeting, the stockholder must bring to the Special Meeting a letter from
the broker, bank or other nominee confirming that stockholder's beneficial
ownership of the shares.
Unless we receive specific instructions to the contrary or unless such
proxy is revoked, shares represented by each properly executed proxy will be
voted: (i) FOR the amendment of the certificate of incorporation to increase
authorized common stock by 50,000,000 shares to 100,000,000 shares of common
stock; and (ii) with respect to any other matters that may properly come before
the Special Meeting, at the discretion of the proxy holders. SIGA does not
presently anticipate that any other business will be presented for action at the
Special Meeting.
Solicitation
SIGA will pay the costs relating to this proxy statement, the proxy card
and the Special Meeting. SIGA may reimburse brokerage firms and other persons
representing beneficial owners of shares for their expenses in forwarding
solicitation material to beneficial owners. Directors, officers and regular
employees may also solicit proxies by telephone, facsimile or other means or in
person. They will not receive any additional payments for the solicitation.
2
PROPOSAL NO. 1
APPROVAL OF THE AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO INCREASE
AUTHORIZED CAPITAL STOCK
The Certificate of Incorporation currently authorizes us to have
50,000,000 shares of common stock. The Board of Directors has approved the
resolution and proposes to amend Article FOURTH of our Restated Certificate of
Incorporation to increase the authorized common stock to 100,000,000 shares of
common stock. Although SIGA has no current plans to issue any additional shares
of common stock, other than in connection with granting stock options to senior
management and directors, we continuously evaluate potential financing,
acquisition and other corporate opportunities, some of which may require the
issuance of our common stock. This proposal would not affect the validity or
status of any currently outstanding shares of common stock. If this proposal is
approved by our stockholders, we plan to file with the Secretary of State of the
State of Delaware a Certificate of Amendment to our Restated Certificate of
Incorporation substantially in the form attached to the proxy statement as Annex
A. Of the 50,000,000 currently authorized shares of common stock, as of June 4,
2007, we had 33,489,812 shares of common stock outstanding, 7,420,912
outstanding options to acquire shares of our common stock, and 8,653,115
warrants to acquire shares of our common stock.
The Board of Directors believes that an increase in the number of shares
of authorized common stock would benefit us and our stockholders by giving us
needed flexibility in our corporate planning in responding to developments in
our business, including possible financing and acquisition transactions, common
stock splits or dividends and for other general corporate purposes. Having such
authorized shares available for issuance in the future would provide us with
greater flexibility and, if necessary, allow common stock to be issued in the
future without expense or delay.
Unless otherwise required by applicable law or regulation, the shares of
common stock to be authorized will be issued without further authorization by
vote or consent of the stockholders and on such terms and for such consideration
as may be determined by the Board of Directors.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" THE
APPROVAL OF THE AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO INCREASE
AUTHORIZED CAPITAL STOCK.
3
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following tables set forth certain information regarding the
beneficial ownership of SIGA's voting securities as of June 4, 2007 of (i) each
person known to SIGA to beneficially own more than 5% of the applicable class of
voting securities, (ii) each director and director nominee of SIGA, (iii) each
Named Executive Officer and (iv) all directors and executive officers of SIGA as
a group. As of June 4, 2007, a total of 33,489,812 shares of common stock were
outstanding. Each share of common stock is entitled to one vote on matters on
which holders of common stock are eligible to vote. The column entitled
"Percentage of Total Voting Stock Outstanding" shows the percentage of total
voting stock beneficially owned by each listed party.
The number of shares beneficially owned is determined under rules
promulgated by the Securities and Exchange Commission, and the information is
not necessarily indicative of beneficial ownership for any other purpose. Under
those rules, beneficial ownership includes any shares as to which the individual
has sole or shared voting power or investment power and also any shares which
the individual has the right to acquire within 60 days of June 4, 2007, through
the exercise or conversion of any stock option, convertible security, warrant or
other right. Unless otherwise indicated, each person or entity named in the
table has sole voting power and investment power (or shares that power with that
person's spouse) with respect to all shares of capital stock listed as owned by
that person or entity.
Ownership of Common Stock
The following tables set forth certain information regarding the
beneficial ownership of SIGA's voting securities as of June 4, 2007 of (i)
each person known to SIGA to beneficially own more than 5% of the applicable
class of voting securities, (ii) each director and director nominee of SIGA,
(iii) each Named Executive Officer, and (iv) all directors and officers of SIGA
as a group. As of June 4, 2007, a total of 33,489,812 shares of common stock
were outstanding. Each share of common stock is entitled to one vote on matters
on which common stockholders are eligible to vote. The column entitled
"Percentage of Total Voting Stock" shows the percentage of total voting stock
beneficially owned by each listed party.
Percentage of Percentage of
Name and Address of Amount of Beneficial Common Stock Total Voting
Beneficial Owner (1) Ownership (2) Outstanding Stock Outstanding
-------------------- -------------------- ------------- -----------------
Beneficial Holders
MacAndrews & Forbes Inc. (3)
35 East 62nd Street
New York, NY 10021 ........................................ 5,620,771(4) 15.9% 15.9%
TransTech Pharma, Inc.
4170 Mendenhall Oaks Parkway
High Point, NC 27265 ...................................... 5,296,634(5) 15.0% 15.0%
Donald G. Drapkin (6) (14)
30 Rockefeller Plaza, 63rd Floor
New York, NY 10020 ........................................ 1,818,326(7) 5.2% 5.2%
Bernard L. Kasten Jr., M.D.(19)
8622 Twilight Tear Lane
Cincinnati, OH 45249 ...................................... 1,672,360(20) 4.8% 4.8%
Officers and Directors
James J. Antal
30952 Steeplechase Dr.
San Juan Capistrano, CA 94704 ............................. 66,154(8) * *
Judy S. Slotkin
888 Park Avenue
NY, NY 10021 ............................................. 108,849(9) * *
4
Thomas E. Constance
1177 Avenue of the Americas,
New York, NY 10036 ........................................ 283,467(10) * *
Steven L. Fasman
35 East 62nd Street
New York, NY 10021 ........................................ 26,000(18) * *
Scott M. Hammer, M.D.
161 Fort Washington Ave.
New York, NY 10032 ........................................ 35,000(11) * *
Adnan M. Mjalli, Ph.D. (14)
4170 Mendenhall Oaks Parkway, Suite 110
High Point, NC 27265 ...................................... 55,000(12) * *
Mehmet C. Oz, M.D.
177 Fort Washington Ave
New York, NY 10032 ........................................ 155,000(13) * *
Eric A. Rose, M.D. (14)
35 East 62nd Street
New York, NY 10021 ....................................... 820,090(15) 2.4% 2.4%
Paul G. Savas (14)
35 East 62nd Street
New York, NY 10021 ....................................... 81,664(16) * *
Michael A. Weiner, M.D.
161 Fort Washington Ave.
New York, NY 10032 ....................................... 142,500(13) * *
Thomas N. Konatich ....................................... 545,000(17) 1.6% 1.6%
Dennis E. Hruby, Ph.D. ................................... 625,000(17) 1.8% 1.8%
All Executive Officers and Directors as a group (twelve
persons) ................................................. 2,943,724(2) 8.1% 8.1%
-------------
* Less than 1%
(1) Unless otherwise indicated the address of each beneficial owner identified
is 420 Lexington Avenue, Suite 408, New York, NY 10170.
(2) Unless otherwise indicated, each person has sole investment and voting
power with respect to the shares indicated. For purposes of this table, a
person or group of persons is deemed to have "beneficial ownership" of any
shares as of a given date which such person has the right to acquire
within 60 days after such date. For purposes of computing the percentage
of outstanding shares held by each person or group of persons named above
on a given date, any security which such person or persons has the right
to acquire within 60 days after such date is deemed to be outstanding for
the purpose of computing the percentage ownership of such person or
persons, but is not deemed to be outstanding for the purpose of computing
the percentage ownership of any other person.
(3) MacAndrews & Forbes Inc. is a direct wholly-owned subsidiary of MacAndrews
& Forbes Holdings Inc., a holding company whose sole stockholder is Ronald
O. Perelman.
(4) Includes 1,764,206 shares of common stock issuable upon exercise of
warrants.
(5) Includes 1,824,412 shares of common stock issuable upon exercise of
warrants.
(6) Mr. Drapkin is a director of TransTech Pharma.
5
(7) Includes 1,145,000 shares of common stock issuable upon exercise of
options, shares of common stock underlying a warrant to purchase up to
347,826 shares of common stock and shares of common stock underlying a
warrant to purchase up to 30,500 shares of common stock (the "Drapkin
September 2001 Investor Warrant"). However, the Drapkin September 2001
Investor Warrant provides that, with certain limited exceptions, such
warrant is not exercisable if, as a result of such exercise, the number of
shares of common stock beneficially owned by Mr. Drapkin and his
affiliates (other than shares of common stock which may be deemed
beneficially owned through the ownership of the unexercised portion of the
Drapkin September 2001 Investor Warrant) would exceed 9.99% of the
outstanding shares of common stock. Does not include shares of common
stock that Mr. Drapkin, as a director and Vice Chairman of Mafco Holdings
Inc. and MacAndrews & Forbes or as director of TransTech Pharma, may be
deemed to beneficially own and as to which Mr. Drapkin disclaims
beneficial ownership.
(8) Includes 55,000 shares of common stock issuable upon exercise of options.
(9) Includes 55,000 shares of common stock issuable upon exercise of options
and 18,244 shares of common stock issuable upon exercise of warrants held
by Ms. Slotkin's spouse, which she may be deemed to beneficially own.
(10) Includes 12,200 shares issuable upon exercise of warrants and 255,000
shares of common stock issuable upon exercise of options.
(11) Includes 35,000 shares issuable upon exercise of options.
(12) Includes 55,000 shares of common stock issuable upon exercise of options.
Does not include shares of common stock that Dr. Mjalli, as a director of
TransTech Pharma, may be deemed to beneficially own and as to which Dr.
Mjalli disclaims beneficial ownership.
(13) Includes 12,500 shares issuable upon exercise of warrants and 130,000
shares issuable upon exercise of options.
(14) Dr. Rose, Dr. Mjalli, and Mr. Savas are directors of TransTech Pharma.
(15) Includes 88,610 shares of common stock issuable upon exercise of warrants
and 630,000 shares of common stock issuable upon exercise of options. Does
not include shares of common stock that Dr. Rose, as a director of
TransTech Pharma, may be deemed to beneficially own and as to which Dr.
Rose disclaims beneficial ownership.
(16) Includes 9,303 shares of common stock issuable upon exercise of warrants
and 55,000 shares issuable upon exercise of options.
(17) Neither of Messrs. Konatich and Hruby own shares of common stock. All
shares listed as beneficially owned by each of Messrs. Konatich and Hruby
are shares issuable upon exercise of stock options.
(18) Includes 25,000 shares issuable upon exercise of options.
(19) Dr. Kasten became our Chief Executive Officer in the third quarter of
2004. Dr. Kasten resigned as Chief Executive Officer of SIGA effective as
of April 30, 2006.
(20) Includes 1,350 shares of common stock issuable upon exercise of warrants
and 1,310,000 shares of common stock issuable upon exercise of options
(21) See footnotes (6)-(20).
6
STOCKHOLDER PROPOSALS
Stockholder proposals to be presented at the 2008 Annual Meeting of
Stockholders, for inclusion in SIGA's proxy statement and form of proxy relating
to that meeting, are to be received by SIGA at its offices in New York, New
York, not later than December 29, 2007.
In addition, Rule 14a-4 of the Exchange Act governs SIGA's use of its
discretionary proxy voting authority with respect to a stockholder proposal that
is not addressed in the proxy statement. With respect to SIGA's 2008 Annual
Meeting of Stockholders, if SIGA is not provided notice of a stockholder
proposal prior to March 13, 2008, SIGA will be allowed to use its discretionary
voting authority when the proposal is raised at the meeting, without any
discussion of the matter in the proxy statement.
OTHER MATTERS
At the date of this proxy statement, management was not aware that any
matters not referred to in this proxy statement would be presented for action at
the Special Meeting. If any other matters should come before the Special
Meeting, the persons named in the accompanying proxy will have discretionary
authority to vote all proxies in accordance with their best judgment, unless
otherwise restricted by law.
BY ORDER OF THE BOARD OF DIRECTORS
/s/ Thomas N. Konatich
------------------------
Thomas N. Konatich
Secretary
Dated: June 15, 2007
7
SIGA TECHNOLOGIES, INC.
PROXY SOLICITED BY THE BOARD OF DIRECTORS
FOR THE SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON JULY 26, 2007
The undersigned hereby appoints Thomas N. Konatich as attorney and proxy
of the undersigned, with full power of substitution, to vote all of the shares
of stock of SIGA Technologies, Inc. which the undersigned may be entitled to
vote at the Special Meeting of Stockholders of SIGA Technologies, Inc. to be
held at the offices of Kramer Levin Naftalis & Frankel LLP, 1177 Avenue of the
Americas, 29th floor, New York, New York 10036, on Thursday, July 26, 2007, at
10:00 a.m. (local time), and at any and all postponements, continuations and
adjournments thereof, with all powers that the undersigned would possess if
personally present, upon and in respect of the following matters and in
accordance with the following instructions, with discretionary authority as to
any and all other matters that may properly come before the meeting.
UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR THE
APPROVAL OF THE AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO INCREASE
AUTHORIZED COMMON STOCK BY 50,000,000 SHARES TO 100,000,000 SHARES OF COMMON
STOCK AS MORE SPECIFICALLY DESCRIBED IN THE PROXY STATEMENT. IF SPECIFIC
INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED IN ACCORDANCE THEREWITH.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE APPROVAL OF THE AMENDMENT TO
THE CERTIFICATE OF INCORPORATION TO INCREASE AUTHORIZED COMMON STOCK BY
50,000,000 SHARES TO 100,000,000 SHARES OF COMMON STOCK.
PLEASE VOTE, SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE
MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE: |X|
1. To approve the amendment to the certificate of incorporation to increase
the authorized common stock by 50,000,000 shares to 100,000,000 shares of
common stock.
|_| FOR |_| AGAINST |_| ABSTAIN
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. IT MAY BE REVOKED
PRIOR TO ITS EXERCISE.
RECEIPT OF NOTICE OF THE SPECIAL MEETING AND PROXY STATEMENT IS HEREBY
ACKNOWLEDGED, AND THE TERMS OF THE NOTICE AND PROXY STATEMENT ARE HEREBY
INCORPORATED BY REFERENCE INTO THIS PROXY. THE UNDERSIGNED HEREBY REVOKES ALL
PROXIES HERETOFORE GIVEN FOR SAID MEETING OR ANY AND ALL ADJOURNMENTS,
POSTPONEMENTS AND CONTINUATIONS THEREOF.
PLEASE VOTE, DATE, SIGN AND PROMPTLY RETURN THIS PROXY IN THE ENCLOSED RETURN
ENVELOPE WHICH IS POSTAGE PREPAID IF MAILED IN THE UNITED STATES.
____________________________________________________________________________
To change the address on your account, please check the box at right and
indicate your new address in the address space above. Please note that changes
to the registered name(s) on the account may not be submitted via this method.
|_|
Signature of Stockholder:_______________________________________________________
Date: ________________
Signature of Stockholder:_______________________________________________________
Date: ________________
PLEASE SIGN EXACTLY AS YOUR NAME APPEARS ON THIS PROXY. WHERE SHARES ARE HELD
JOINTLY, EACH HOLDER SHOULD SIGN. WHEN SIGNING AS EXECUTOR, ADMINISTRATOR,
ATTORNEY, TRUSTEE OR GUARDIAN, PLEASE GIVE FULL TITLE AS SUCH. IF SIGNER IS A
CORPORATION, PLEASE SIGN IN FULL CORPORATE NAME BY DULY AUTHORIZED OFFICER,
GIVING FULL TITLE AS SUCH. IF SIGNER IS A PARTNERSHIP, PLEASE SIGN IN FULL
PARTNERSHIP NAME BY AUTHORIZED PERSON.
ANNEX A
CERTIFICATE OF AMENDMENT
OF
THE RESTATED
CERTIFICATE OF INCORPORATION
OF
SIGA TECHNOLOGIES, INC.
Pursuant to Section 242 of the General Corporation Law of the State of
Delaware (the "DGCL"), the undersigned, SIGA Technologies, Inc., a Delaware
corporation (the "Corporation"), does hereby certify as follows:
FIRST: The name of the Corporation is SIGA Technologies, Inc. and the name
under which the Corporation was originally incorporated was Siga
Pharmaceuticals, Inc.
SECOND: The original Certificate of Incorporation of the Corporation was
filed with the Secretary of State of the State of Delaware (the "Secretary of
State") on December 28, 1995, and the Restated Certificate of Incorporation of
the Corporation was filed with the Secretary of State on April 27, 2000 (as so
amended and restated, the "Certificate of Incorporation").
THIRD: Pursuant to Section 242(a)(3) of the DGCL, the first paragraph of
Article FOURTH is deleted in its entirety and the following is hereby inserted
as the first paragraph of Article FOURTH of the Certificate of Incorporation:
"FOURTH: The total number of shares of stock which the Corporation shall
have the authority to issue is one hundred and ten million (110,000,000) of
which one hundred million (100,000,000) shares of par value of One Hundredth of
One Cent ($0.0001) each, amounting to Ten Thousand Dollars ($10,000), shall be
Common Stock, and of which ten million (10,000,000) shares of par value of One
Hundredth of One Cent ($0.0001) each, amounting to One Thousand Dollars
($1,000), shall be Preferred Stock."
The remainder of Article FOURTH shall be unaffected and remain unchanged
by the Certificate of Amendment.
FIFTH: This Certificate of Amendment shall become effective as of the
close of business on the date this Certificate of Amendment is filed with the
Secretary of State.
IN WITNESS WHEREOF, this Certificate of Amendment, having been duly
adopted by the Board of Directors and the stockholders of the Corporation, has
been executed this [__________] day of [______], 2007.
SIGA TECHNOLOGIES, INC.
By: _________________________________________________
Name: ________________________________________
Title: ________________________________________